Antimyoclonic action of piracetam.
Five patients with myoclonus were treated with oral piracetam (8-9 g/day). All patients had action-sensitive and/or stimulus-sensitive myoclonus and enhanced amplitude of somatosensory evoked potentials. Piracetam produced a marked reduction of the myoclonus in the five subjects without side effects. In view of its excellent tolerance and synergism with other antimyoclonic drugs, we consider piracetam to be a very valuable drug for the treatment of patients with myoclonus of any origin.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004569:Electroencephalography; D004831:Epilepsies, Myoclonic / Q000188:drug therapy* / Q000503:physiopathology; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects; D005260:Female; D006801:Humans; D010889:Piracetam / Q000627:therapeutic use*; D011760:Pyrrolidinones / Q000627:therapeutic use*
D011760:Pyrrolidinones; D010889:Piracetam